

Lifeline Drugs & Pharma Limited

Regd Office : 17, 3rd Floor, Zaveri Bhavan, 85/87, Old Hanuman Lane, Kalbadevi Road, Mumbai-400 002

Statement of Unaudited Financial Results for the Quarter ended 30th June 2013

Rs. in Lacs

Sr. No.	Particulars	3 Months ended 30.06.2013	Preceding 3 Months ended 31.03.2013	Corresponding 3 Months ended 30.06.2012	Year to date figures as on 31.03.2013
		Un-Audited	Audited	Un-Audited	Audited
1	Income from Operations				
	a) Net Sales/Income from Operations	958.24	-	-	-
	b) Other Operating Income	-	-	-	-
	Total Income from Operations (Net)	958.24	-	-	-
2	Expenses				
	(a) Cost of Material Consumed	-	-	-	-
	(b) Purchases of Stock-in-trade	944.63	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-
	(d) Employees Benefit Expenses	1.95	1.03	0.58	3.75
	(e) Depreciation & Amortization Expenses	-	-	-	-
	(f) Other Expenses	1.50	(3.78)	1.64	4.51
	Total Expenses	948.08	(2.75)	2.22	8.26
3	Profit/(Loss) from Operations before other income, finance cost and exceptional Expenses (1-2)	10.16	2.75	(2.22)	(8.26)
4	Other Income/(Loss)	-	3.46	6.38	28.64
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	10.16	6.21	4.16	20.38
6	Finance Costs	-	-	-	-
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (3-4)	10.16	6.21	4.16	20.38
8	Exceptional Items	-	-	-	-
9	Profit(+)/Loss(-) from ordinary activities before Tax (7-8)	10.16	6.21	4.16	20.38
10	Tax Expense	-	-	-	6.30
11	Net Profit (+)/Loss(-) from ordinary activities after tax (9-10)	10.16	6.21	4.16	14.09
12	Extra Ordinary Items (Net of Tax Expense of Rs. Lac)	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11-12)	10.16	6.21	4.16	14.09
14	Share of Profit/(Loss) of Associates*	-	-	-	-
15	Minority Interest*	-	-	-	-
16	Net Profit (+)/Loss(-) after tax, minority interest and Share of Profit / (Loss) of Associates (13-14-15)	10.16	6.21	4.16	14.09
17	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	307.40	307.40	24.00	307.40
18	Reserves excluding revaluation Reserves as per last Balance Sheet	-	-	-	968.27
19	Earning Per Share (before extra-ordinary items) of Rs. 10/- each (not annualized)				
(i)	a) Basic	0.33	0.20	1.73	0.46
	b) Diluted	0.33	0.20	1.73	0.46
19	Earning Per Share (after extra-ordinary items) of Rs. 10/- each (not annualized)				
(ii)	a) Basic	0.33	0.20	1.73	0.46
	b) Diluted	0.33	0.20	1.73	0.46
A	PARTICULARS OF SHAREHOLDING				
	Public Shareholding				
	- Number of Shares	3,071,500	3,071,500	239,265	3,071,500
	- Percentage of Share Holding	99.92	99.92	99.69	99.92
18	Promoter and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	-	-	-	-
	- Percentage of Shares (as a % of the total Share Capital of the Company)	-	-	-	-
	b) None-Encumbered				
	- Number of Shares	2,500	2,500	735	2,500
	- Percentage of Shares (as a % of the total Shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total Share Capital of the Company)	0.08	0.08	0.31	0.08
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the Quarter	Nil			
	Disposed during the Quarter	Nil			
	Remaining Unresolved at the end of Quarter	Nil			
	Received during the Quarter	Nil			

Notes :

- Segmental Report for the Quarter as per AS-17 is not applicable for the current Quarter.
- The figures of preceding Quarter ended 31st March 2013 are the balancing figures between Audited figures in respect of full financial year and the published year to date figures upto the 3rd Quarter of the Previous Financial Year.
- Above results were reviewed by Audit Committee taken on record in Board Meeting held on 14th August 2013.
- Statutory Auditors of the Company have carried "Limited Review" for above Results.

For Lifeline Drugs & Pharma Limited

S/d-

Alok Behera

Managing Director

Place : Mumbai

Date : 14th August 2013